Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator

Jun 02, 2023

Posted by Societal CDMO

Societal CDMO Selected by Xequel Bio to Provide CDMO Services to Support Ongoing Clinical Development of iNexin™

Jun 02, 2023

Posted by Societal CDMO

Societal CDMO Signs Multiple Project Expansion Agreements With Existing Customers

Jun 02, 2023

Posted by Societal CDMO

Societal CDMO Selected by Longboard Pharmaceuticals to Provide CDMO Services to Support Clinical Development of LP352

Jun 02, 2023

Posted by Societal CDMO

Societal CDMO Announces U.S. FDA Approval for Manufacturing of Commercial Tablet at Gainesville, Georgia Site

Jun 02, 2023

Posted by Societal CDMO

Freshfields Advises SERB Pharmaceuticals on its U.S. Partnership with SFJ Pharmaceuticals

Jun 01, 2023

Posted by Freshfields

Key Takeaways from the 21st Annual Biomed Israel Conference

Jun 01, 2023

Posted by Freshfields

Ongoing Initiatives at the USPTO and FDA and Their Potential Impact on the Life Sciences Industry in the United States

Jun 01, 2023

Posted by Freshfields

FTC v. Amgen/Horizon: FTC’s Pursuit of a Novel Theory Signals Greater Scrutiny on the Horizon for Pharmaceutical Mergers

Jun 01, 2023

Posted by Freshfields